Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

Recruiting now

Conditions studied: Hematologic Malignancies

In brief

CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.

Key facts

Study ID

NCT04546945

Run by

Asmaa Hassan mohamed Abdel Mawjoud

People needed

38

Starts

2027-03-20

Expected to finish

2027-12-30

Last updated by the study team

2026-03-18

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients with hematologic malignancies.
• Newly diagnosed

You may not qualify if…

• Patients with hematologic disorders other than hematologic malignancies.

Where it is running

• Assiut university — Asyut, Egypt (enrolling)
• Assiut University — Asyut, Egypt

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.